IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

HW

nt: Steven D. Girouard et al.

Steven D. Gilouald et al

E: METHOD AND APPARATUS FOR CELL AND ELECTRICAL THERAPY OF LIVING

TISSUE

Docket No.:

279.597US1

November 25, 2003

Examiner:

Filed:

Unknown

Serial No.: 10/722,115

Due Date: N/A

Group Art Unit: 1744

MS Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

We are transmitting herewith the following attached items (as indicated with an "X"):

X A return postcard.

X A Communication Concerning Related Applications (2 pgs.).

X A Supplemental Information Disclosure Statement (2 pgs.), Form 1449 (2 pgs.), and copies of 25 cited documents.

If not provided for in a separate paper filed herewith, Please consider this a PETITION FOR EXTENSION OF TIME for sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

Customer Number 21186

Atty: Zhengnian Tang Reg. No. 55,666

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 13 maday of June, 2005.

Name

Signature

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

(GENERAL)

0/722,11<u>5</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Steven D. Girouard et al.

Examiner: Unknown

Serial No.:

10/722,115

Group Art Unit: 1744

Filed:

November 25, 2003

Docket: 279.597US1

Title:

METHOD AND APPARATUS FOR CELL AND ELECTRICAL THERAPY OF

LIVING TISSUE

COMMUNICATION CONCERNING RELATED APPLICATIONS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Applicants would like to bring to the Examiner's attention the following related applications in the above-identified patent application:

Serial/Patent No. 11/017,627	Filing Date December 20, 2004	Attorney Docket 279.759US1	Title EPICARDIAL PATCH INCLUDING ISOLATED EXTRACELLULAR MATRIX WITH PACING ELECTRODES
11/017,237	December 20, 2004	279.760US1	USE OF EXTRACELLULAR MATRIX AND ELECTRICAL THERAPY
11/017,432	December 20, 2004	279.806US1	IMPLANTABLE MEDICAL DEVICES COMPRISING ISOLATED EXTRACELLULAR MATRIX

Page 2 Dkt: 279.597US1

Title: METHOD AND APPARATUS FOR CELL AND ELECTRICAL THERAPY OF LIVING TISSUE

11/017,238

December 20, 2004

279.811US1

LEAD ELECTRODE INCORPORATING EXTRACELLULAR MATRIX

Continuations and divisionals may be later filed on the cases listed above, or cited to the Examiner in any previous Communication Concerning Related Applications. Applicant requests that the Examiner review all continuations and divisionals of the above-listed or previously-cited patent applications before allowing the claims of the present patent application.

Respectfully submitted,

STEVEN D. GIROUARD ET AL.

By Applicants' Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938

Minneapolis, MN 55402

(612) 373-6965

By

Date 6/10/2005

Zhengnian Tang

Reg. No. 55,666

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 1374 day of June, 2005.





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Steven D. Girouard et al. Examiner:

Unknown

Serial No.:

10/722,115

Group Art Unit:

1744

Filed:

November 25, 2003

Docket:

279.597US1

Title:

METHOD AND APPARATUS FOR CELL AND ELECTRICAL THERAPY OF

LIVING TISSUE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 et. seq., the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Supplemental Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Supplemental Information Disclosure Statement considered.

EMENTAL INFORMATION DISCLOSURE STATEMENT

No :10/722,115

ing Date: November 25, 2003

Title: METHOD AND APPARATUS FOR CELL AND ELECTRICAL THERAPY OF LIVING TISSUE

Pursuant to 37 C.F.R. 1.98(a)(2), Applicant believes that copies of cited U.S. Patents and Published Applications are no longer required to be provided to the Office. Notification of this change was provided in the United States Patent and Trademark Office OG Notices dated October 12, 2004. Thus, Applicant has not included copies of any Published Applications cited with this submission. Should the Office require copies to be provided, Applicant respectfully requests that notice of such requirement be directed to Applicant's below-signed representative. Applicant acknowledges the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2).

The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

STEVEN D. GIROUARD ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A. P.O. Box 2938

Minneapolis, MN 55402

(612) 373-6965

Date 6/10/2005

Zhengnian Tang

Reg. No. 55,666

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 1374 day of June, 2005.

Name

Signature

PTO/SB/084(10-01)
Approved for use through 10/31/2002. OMB 651-0031
US Patent & Trajemen's Office: U.S. DEPARTMENT OF COMMERCE
OMBERCE
Indee the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. for form 1449A/PTO Complete if Known RMATION DISCLOSURE 10/722,115 **Application Number** TATEMENT BY APPLICANT November 25, 2003 Filing Date (Use as many sheets as necessary) **First Named Inventor** Girouard, Steven **Group Art Unit** 1744 **Examiner Name** Unknown Attorney Docket No: 279.597US1 Sheet 1 of 2

US PATENT DOCUMENTS				
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
	US- 2002/0172663 A1	11/21/2002	Palasis, M. , et al.	01/23/2002
	US- 2003/0087867 A1	05/08/2003	Vogels, R. V., et al.	08/19/2002

	OTHE	R DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		BURTON, D. Y., et al., "The Incorporation of an Ion Channel Gene Mutation	
		Associated with the Long QT Syndrome (Q9E-hMiRPI) in a Plasmid Vector for	-
		Site-Specific Arrhythmia Gene Therapy: In Vitro and In Vivo Feasibility Studies",	İ
		Human Gene Therapy, 14, (2003), 907-922	<u> </u>
		DEL MONTE, F., et al., "Targeting Calcium Cycling Proteins in Heart Failure	
		Through Gene Transfer", The Journal of Physiology, 546(1), (2002), 49-61	<u> </u>
		DONAHUE, J. K., et al., "Focal Modification of Electrical Conduction in the Heart	
		by Viral Gene Transfer", Nature Medicine, 6(12), (2000),1395-1398	<u> </u>
		HAMAWY, A. H., et al., "Cardiac Angiogenesis and Gene Therapy: A Strategy for Myocardial Revascularization", Current Opinion in Cardiology, 14, (1999),	
		515-522	
		HONG, Y. S., et al., "Localized Immunosuppression in the Cardia Allograft	
		Induced by a New Liposome-Mediated IL-10 Gene Therapy", The Journal of	
		Heart and Lung Transplantation, 21, (2002), 1188-1200	
	· · · · · · · · · · · · · · · · · · ·	HUQ, F., et al., "Session 5: Cellular and Subcellular Basis of Remodeling -	
	•	Modulating Signalling Pathways in Hypertrophy and Heart Failure by Gene	
		Transfer", Journal of Cardiac Failure, 8(6)(Suppl.), (2002), S389-S400	
		JAYAKUMAR, MD, J., et al., "Gene Therapy for Myocardial Prevention -	
		Transfection of Donor Hearts With Heat Shock Protein 70 Gene Protects Cardiac	
		Function Against Ischemia-Reperfusion Therapy", Circulation, 102 (Suppl. III),	
		(2000), III-302-III-306	ļ <u>.</u>
		KOCH, W. J., et al., "Gene Transfer of β-Adrenergic Signalling Components for	
		Heart Failure", Journal of Cardiac Failure, 8(6) (Suppl.), (2002), S526-S531	ļ
		KOZARSKY, K. F., "Gene Therapy for Cardiovascular Disease", Current	
		Opinion in Pharmacology, 1, (2001), 197-202	ļ
		LEE, L. Y., et al., "Exogenous Control of Cardiac Gene Therapy: Evidence of	
		Regulated Myocardial Transgene Expression After Adenovirus and Adeno-	,
·		Associated Virus Transfer of Expression Cassettes Containing Corticosteroid Response Element Promoters", J Thorac Cardiovasc Surg. 118, (1999), 26-35	
		LIN. H., "Specific Region of the c-myc Promoter is Responsive to Electric and	
		Magnetic Fields", Journal of Cellular Biochemistry, 54, (1994), 281-288	
		magnetic ricids, godinar of Celidiar Biochemistry, 04, (1004), 201 200	

EXAMINER

DATE CONSIDERED

PTO/SB/08A(10-01)

Approved for use through 10/31/2002, OMB 651-0031

US Patent & Trademark Office: U.S. OEPARTMENT OF COMMERGE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO	Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	10/722,115	
(Use as many sheets as necessary)	Filing Date	November 25, 2003	
	First Named Inventor	Girouard, Steven	
	Group Art Unit	1744	
	Examiner Name	Unknown	
Sheet 2 of 2	Attorney Docket No: 2	279.597US1	

	OTHER	R DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		LIN, H., "Regulating Genes with Electromagnetic Response Elements", Journal	
		of Cellular Biochemistry, 81, (2001), 143-148	<u> </u>
	-	MACNEILL, MD, B. D., et al., "Targeting Signaling Pathways in Heart Failure by Gene Transfer", Current Atherosclerosis Reports, 5, (2003), 178-185	
		MÁRBAN, E., et al., "Gene Therapy for Cardiac Arrhythmias", Cold Spring	
		Harbor Symposia on Quantitative Biology, Vol. LXVII - The Cardiovascular	1
		System, Published by Cold Spring Harbor Laboratory Press,(2002), 527-531	
		NUSS, H. B., et al., "Reversal of Potassium Channel Deficiency in Cells from	
		Failing Hearts by Adenoviral Gene Transfer: A Prototype for Gene Therapy for	
		Disorders of Cardiac Excitability and Contractility", Gene Therapy, 3, (1996), 900-912	
		RADISIC, M., "From the Cover: Functional Assembly of Engineered	
		Myocardium by Electrical Stimulation of Cardiac Myocytes Cultured on	
		Scaffolds", Proc Natl Acad Sci U S A., 101(52), (December 28, 2004), 18129- 18134	
	-	ROSS, JEFFREY, "EPICARDIAL PATCH INCLUDING ISOLATED	
		EXTRACELLULAR MATRIX WITH PACING ELECTRODES", Application Serial	
		No. 11/017,627, filed December 20, 2004 (Attorney Docket No. 279.759US1).	
		87 pgs.	
		ROSS, JEFFREY, et al., "USE OF EXTRACELLULAR MATRIX AND	
		ELECTRICAL THERAPY", Application Serial No. 11/017,237, filed December	
		20, 2004 (Attorney Docket No. 279.760US1), 89 pgs.	
		RUBENSTRUNK, A., "Transcriptional Activation of the Metallothionein I Gene	
		by Electric Pulses in vivo: Basis for the Development of a New Gene Switch	
		System", The Journal of Gene Medicine, 5, (2003), 773-783	
		RUTANEN, J., et al., "Progress and Prospects - Post-Intervention Vessel	
		Remodeling", Gene Therapy, 9, (2002),1487-1491	İ
		SIH, HARRIS J., "IMPLANTABLE MEDICAL DEVICES COMPRISING	
		ISOLATED EXTRACELLULAR MATRIX", Application Serial No. 11/017,432,	
		filed December 20, 2004 (Attorney Docket No. 279.806US1), 87 pgs.	
_		WALTHER, W., et al., "Cell Type Specific and Inducible Promoters for Vectors in	
		Gene Therapy as an Approach for Cell Targeting", Journal of Molecular	
		Medicine, 74, (1996), 379-392	_
		WATTANAPITAYAKUL, S. K., et al., "Recent Developments in Gene Therapy for	
		Cardiac Disease", Biomedical & Pharmacotherapy, 54, (2000),487-504	<u> </u>
		WESTLUND, RANDY, "LEAD ELECTRODE INCORPORATING	
		EXTRACELLULAR MATRIX", Application Serial No. 11/017,238, filed December	
		20, 2004 (Attorney Docket No. 279.811US1), 85 pgs.	
		WYMAN, T, et al., "Promoter-Activated Expression of Nerve Growth Factor for	
		Treatment of Neurodegenerative Diseases", Gene Therapy, 6, (1999), 1648-	
		1660	
	·		

EXAMINER DATE CONSIDERED